[JAMA Article] New Oncology Drugs Command High Price Tags Despite Lack of Improved Survival
In an article published in JAMA Internal Medicine, researchers assessed the costs of 44 new oncology drugs. Surprisingly, they found [...]
ICER Releases Final Evidence Report for Hypertrophic Cardiomyopathy Drug
The Institute for Clinical and Economic Review (ICER) has published its Final Evidence Report for mavacamten, produced by MyoKardia and [...]
Flatiron ResearchX On-Demand Webinar on RWE in Regulatory Submissions
Flatiron ResearchX invited real world evidence (RWE) and pharma leaders to discuss how RWE impacts submissions to regulatory bodies. Available [...]
eBook on Rare Disease Therapies and Marketing Now Available
Rare Disease Advisor is offering a free eBook on rare disease (RD) trends and marketing efforts. The eBook details highly [...]
Amgen’s Patent Thicket Strategy Yields Billions in Drug Sales for TNF Inhibitor Enbrel
Amgen has employed a powerful strategy to maintain its monopoly on Enbrel, a drug that targets tumor necrosis factor (TNF) [...]
Veradigm Details the Power of Linked Healthcare Data in RWD Research
Sources of real world data (RWD) such as claims data, surveillance data gathered from disease registries, and electronic health record [...]
ICER Publishes Annual Hit List of 10 Drugs With Unsupported Price Hikes
The Institute for Clinical and Economic Review (ICER) has released its most recent report on Unsupported Price Increases (UPIs) for 2020. [...]
AllStripes Announces $50 Million in Series B Funding to Advance Rare Disease Research
AllStripes has raised $50 million in Series B Funding, led by Lux Capital. As a result, the organization has initiated [...]
Cerner’s First Chief Health Officer Seeks to Leverage EHR RWD to Predict Disease and Improve Patient Outcomes
According to Cerner, Nasim Afsar, MD, MBA, MHM will take on the position of Chief Health Officer in January 2022. [...]
Updated Promising Zone Design Improves Workflow and Clinical Trial Design for Biotechs
Promising Zone Design was first introduced a decade ago as a method to estimate sample size. The method is still [...]
RWE Expert and Economist Details Future Global Market Access and Pricing Trends
Economist Ulf Staginnus shared his thoughts on future trends for market access and drug pricing in a recent discussion with [...]
Will Mark Cuban’s PBM Deliver on Pricing Promises?
Mark Cuban’s new pharmacy benefit manager (PBM) venture and employer-run EmsanaRx are two of the latest players to enter the [...]
New Report Considers Use of Oncology RWE in Successful Submissions to the FDA
In a recent article published in Clinical Cancer Research, investigators analyzed successful submissions of oncology drugs to the Food and [...]
CEVR Leaders Publish NEJM Article on Determining Value Using Cost-Effectiveness Analyses
Peter Neumann, Sc.D., Joshua Cohen, Ph.D., and Daniel Ollendorf, Ph.D. of the Center for the Evaluation of Value and Risk [...]
Certara Leaders Discuss Leveraging RWD to Advance R&D and Meet Global Payers’ Needs
Certara’s Lee Stern and Shawn Bates shared their thoughts on how real world data (RWD) can be leveraged to meet [...]
Register Now for Tuesday Webinar on Understanding Drug Expenditure Dynamics From 1995 to 2020
IQVIA will hold a webinar on Tuesday, November 16, at 10:00 AM EST. Speakers will discuss healthcare spending trends since [...]
Pharmacogenomics and Personalized Medicine in Type 2 Diabetes Mellitus: Potential Implications for Clinical Practice
Download Article [PDF] Poongothai Venkatachalapathy, 1 Sruthi Padhilahouse, 1 Mohan Sellappan, 1 Tharunika Subramanian, 2 Shilia Jacob Kurian, 3 Sonal [...]
How Big Data Analytics is set to Power Precision Medicine
How Big Data Analytics is set to Power Precision Medicine Visualize a scenario where you are (god forbid) gravely ill, [...]
Decentralized Clinical Research Will Be A Paradigm-Shifting Trend
The field of clinical research is on the precipice of change, and for good reason. Traditional clinical trials and processes [...]
Using real world evidence in the development
Learn about the differences between real world data and real world evidence. by Andrew Roddam and Sumitra Shantakumar Traditional randomized [...]
Health Economics and Outcomes Research (HEOR) Services Market – Sportlineng
//bit.ly/3mZzlVV Health Economics and Outcomes Research (HEOR) Services Market: Axtria, Pharmaceutical Product Development (PPD), Avalon Health Economics, ICON, IQVIA, … [...]
93,000 Died From Opioid Overdoses in 2020, Hundreds of Billions of Dollars Needed to Fix It
93,000 Died From Opioid Overdoses in 2020, Hundreds of Billions of Dollars Needed to Fix It Thousands of people died [...]
ICON Announces the Expansion of its Accellacare Site Network – 10.11.2021
ICON plc, (NASDAQ: ICLR) a global provider of drug development and commercialisation services to pharmaceutical, biotechnology, medical device, and government [...]
Alzheimer’s drug cited as Medicare premium jumps by $21.60
By RICARDO ALONSO-ZALDIVAR WASHINGTON (AP) — Medicare’s “Part B” outpatient premium will jump by $21.60 a month in 2022, one [...]
We Only Think We’re Making Our Own Choices. It Matters How Options Are Framed
You might not know it, but when you gave your partner some choices for dinner after work this evening, you [...]